63 completed, 14 active not recruiting, 9 terminated, 5 recruiting. 58 Phase 2, 24 Phase 1, 9 Phase 3, 4 Not applicable, 1 Early Phase 1.
Follow Urethral Neoplasms: new trials by email Literature Review of Urethral Neoplasms trials Research Report on Urethral Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| DESTINY-PANTUMOUR04 Trastuzumab deruxtecan - Adenocarcinoma (NOS), Anal Cancer | Recruiting | AstraZeneca | 100 | 2025-09-18 | 2026-09-25 | |
| Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial Carcinoma Add-on effect of adding tamivarotene (AM80) to gemcitabine, cisplatin, and nivolumab combination therapy - Urothelial Carcinoma Bladder, Urothelial Carcinoma of the Renal Pelvis and Ureter | Phase 2 | Recruiting | Nagoya University | 43 | 2025-05-01 | 2025-08-14 |
| Agnostic Therapy in Rare Solid Tumors Nivolumab - Urachal Cancer, Parathyroid Carcinoma | Phase 2 | Active not recruiting | Instituto do Cancer do Estado de São Paulo | 28 | 2024-07-16 | 2026-10-13 |
| A Novel Imaging Protocol in Use to Identify Lymph Nodes and Organs of Interest Electromagnetic Guided Laparoscopy, Ultrasound - Urologic Cancer, Urologic Neoplasms | Not applicable | Completed | Brigham and Women's Hospital | 7 | 2023-08-30 | 2026-09-30 |
| 64Cu-GRIP B in Patients With Advanced Malignancies Copper-64 labeled Granzyme B (64Cu-GRIP B), Positron Emission Tomography (PET) - Prostate Cancer, Renal Cancer | Phase 1 / Phase 2 | Recruiting | Rahul Aggarwal | 91 | 2023-05-25 | 2026-03-17 |
| Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy Biospecimen Collection, Bone Scan, Computed Tomography - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 24 | 2022-07-07 | 2026-09-22 |
| Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study Avelumab, Biospecimen Collection, Bone Scan - Advanced Bladder Urothelial Carcinoma, Advanced Renal Pelvis Urothelial Carcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 654 | 2022-06-03 | 2026-10-26 |
| Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma Ipilimumab, Nivolumab, Tocilizumab - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 35 | 2021-09-23 | 2026-09-16 |
| ARID1A and/or KDM6A Mutation and CXCL13 Expression Diagnostic Laboratory Biomarker Analysis, Nivolumab, Relatlimab - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 6 | 2021-09-21 | 2026-10-06 |
| Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma Pembrolizumab, Propranolol Hydrochloride, Nivolumab - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 2 | Active not recruiting | Emory University | 6 | 2021-05-20 | 2026-02-19 |
| Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma Avelumab, AVB-S6-500 - Urothelial Carcinoma | Phase 1 | Active not recruiting | University of Oklahoma | 19 | 2020-02-17 | 2026-03-13 |
| Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma Atezolizumab, Biopsy, Biospecimen Collection - Advanced Bladder Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 47 | 2019-06-05 | 2024-07-26 |
| Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors Biospecimen Collection, Bone Scan, Cabozantinib S-malate - Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 314 | 2019-05-13 | 2026-10-27 |
| MRx0518 in Patients With Solid Tumours Waiting Surgical Removal of the Tumour MRx0518 Capsules, MRx0518/placebo Capsules - Melanoma, Breast Cancer | Phase 1 | Unknown | Imperial College London | 120 | 2019-04-10 | 2022-08-11 |
| Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate Carboplatin, Cisplatin, Docetaxel - Bladder Small Cell Neuroendocrine Carcinoma, Castration-Resistant Prostate Carcinoma | Phase 1 | Active not recruiting | Jonsson Comprehensive Cancer Center | 15 | 2019-01-11 | 2025-11-12 |
| Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer Avelumab, Cisplatin, Fluorouracil - Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Stage II Bladder Cancer AJCC v8 | Phase 2 | Completed | Mayo Clinic | 2 | 2018-09-19 | 2023-01-06 |
| Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer Atezolizumab, Biopsy Procedure, Biospecimen Collection - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 72 | 2018-07-20 | 2026-07-31 |
| Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Rucaparib - Bladder Cancer, Urothelial Carcinoma | Phase 2 | Terminated | pharmaand GmbH | 97 | 2018-06-01 | 2023-06-09 |
| Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma Immune checkpoint inhibitor targeting PD1 - Renal Cell Carcinoma, Urothelial Carcinoma | Active not recruiting | Fox Chase Cancer Center | 15 | 2017-11-27 | 2026-05-22 | |
| Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma Atezolizumab, Guadecitabine - Urothelial Carcinoma | Phase 2 | Active not recruiting | Fox Chase Cancer Center | 21 | 2017-11-27 | 2021-11-04 |
Showing 20 of 95. Sign in to see all of them.
Urinary Bladder Neoplasms (87) · Ureteral Neoplasms (41) · Carcinoma, Transitional Cell (24) · Prostatic Neoplasms (16) · Carcinoma, Renal Cell (13) · Penile Neoplasms (12) · Anus Neoplasms (11) · Neoplasms (11) · Testicular Neoplasms (11) · Vaginal Neoplasms (11) · Vulvar Neoplasms (11) · Endometrial Neoplasms (10) · Pancreatic Neoplasms (10) · Uterine Cervical Neoplasms (10)
Female Urogenital Diseases (95) · Female Urogenital Diseases and Pregnancy Complications (95) · Male Urogenital Diseases (95) · Urethral Diseases (95) · Urogenital Diseases (95) · Urologic Diseases (95) · Neoplasms by Site (94) · Urogenital Neoplasms (93) · Urologic Neoplasms (92) · Urinary Bladder Diseases (86) · Neoplasms (84) · Neoplasms by Histologic Type (43) · Neoplasms, Glandular and Epithelial (41) · Ureteral Diseases (40) · Carcinoma (39)
Gemcitabine (25) · Cisplatin (18) · Carboplatin (10) · Paclitaxel (9) · Docetaxel (6) · Doxorubicin (6) · Nivolumab (6) · Specimen Handling (6) · Magnetic Resonance Spectroscopy (5) · pembrolizumab (5) · Fluorouracil (4) · Methotrexate (4) · Radiotherapy (4) · Vinblastine (4) · avelumab (4)
National Cancer Institute (NCI) (19) · M.D. Anderson Cancer Center (9) · Eastern Cooperative Oncology Group (6) · SWOG Cancer Research Network (6) · European Organisation for Research and Treatment of Cancer - EORTC (4) · Cardiff University (3) · Eli Lilly and Company (3) · AstraZeneca (2) · Dr Anders Ullén (2) · Emory University (2) · Fox Chase Cancer Center (2) · Memorial Sloan Kettering Cancer Center (2) · Regeneron Pharmaceuticals (2) · Wake Forest University Health Sciences (2) · Abramson Cancer Center at Penn Medicine (1)
United States (76) · United Kingdom (11) · Canada (10) · Spain (10) · France (8) · Italy (8) · Germany (7) · Netherlands (7) · Denmark (5) · Belgium (4) · Israel (4) · Japan (4) · Puerto Rico (4) · South Korea (4) · Hungary (3)
Bruce J. Roth, MD (3) · Andrea B Apolo (2) · Andrea B Apolo, M.D. (2) · Arlene Siefker-Radtke, MD (2) · Daniel P. Petrylak, MD (2) · Dean F. Bajorin, MD (2) · Joaquim Bellmunt, MD, PhD (2) · Robert Dreicer (2) · Robert Dreicer, MD, FACP (2) · William P. Tew, MD (2) · Abhishek Tripathi, MD (1) · Andrea Necchi, MD (1) · Andreas Boehle, MD (1)
PMID 19949018, PMID 22002018, PMID 35031545, PMID 11001674, PMID 12448661, PMID 12767086, PMID 15073851, PMID 15911238, PMID 1607913, PMID 16330205, PMID 18024869, PMID 18459175, PMID 18470481, PMID 18501081, PMID 18685414, PMID 19269798, PMID 19371909, PMID 19786668, PMID 20068553, PMID 22162575, PMID 22370319, PMID 22480131, PMID 22819172, PMID 23329066, PMID 25427282, PMID 26001531, PMID 26149529, PMID 26582660, PMID 26926681, PMID 27020837, PMID 28916371, PMID 29853658, PMID 30552156, PMID 31301962, PMID 31356140, PMID 31390274, PMID 31648851, PMID 31753727, PMID 32645282, PMID 32915679, PMID 33046869, PMID 33068794, PMID 33160359, PMID 33989025, PMID 33991512, PMID 34030643, PMID 34795131, PMID 35168844, PMID 35388003, PMID 35537412
U10CA032102 (6), U10CA031946 (4), P30CA016672 (3), U10CA180821 (3), P50CA091846 (2), U10CA021115 (2), UM1CA186717 (2), 2014 (1), 2015 (1), 2017 (1), N01CM00038 (1), N01CM62201 (1), N01CM62205 (1), N01CM62209 (1), P30CA012197 (1)